NEOD001
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Amyloidosis
Conditions
Primary Amyloidosis
Trial Timeline
Apr 1, 2013 → Aug 9, 2016
NCT ID
NCT01707264About NEOD001
NEOD001 is a phase 1/2 stage product being developed by Prothena for Primary Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01707264. Target conditions include Primary Amyloidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03154047 | Phase 2 | Terminated |
| NCT02613182 | Phase 2 | Terminated |
| NCT02312206 | Phase 3 | Terminated |
| NCT01707264 | Phase 1/2 | Completed |
Competing Products
20 competing products in Primary Amyloidosis